Phase 1 N=37 A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients
Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 3; 3; 25; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=32 Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
Pulmonary Arterial Hypertension
Primary: Number of Subjects Not Able to Tolerate Ambrisentan — 4 participants
Phase 2 N=683 A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)
Migraine
Primary: Percentage of Participants With Pain Freedom at Two Hours Post-dose — 10.9; 35.2; 38.3; 31.2 Percentage of Participants — p=<0.001
Phase 1 N=13 ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma (NSCLC)
Primary: Patients Affected by Treatment-related Morbidities — 12 participants
Phase 4 N=140 Naltrexone for Heavy Drinking in Young Adults
Alcohol Consumption · Alcoholic Intoxication · Alcoholism
Primary: Frequency of Heavy Episodic Drinking — 34.3; 33.4 percentage of heavy drinking days
Phase 1 N=304 A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
Tumors Characterized by Genetic Abnormalities of ALK
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 3 N=34 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence
Mania · Hypomania · Cocaine Abuse
Primary: Cocaine Use Determined by Urine Analysis — 62.50; 50.00 percentage of participants no cocaine — p=.4637
Phase 4 N=7 Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section
Contraception
Primary: Successful Retention of IUD — 7 participants
Phase 2 N=33 RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy. — 23…
Phase 1 N=9 A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal
Pharmacokinetics · Tolerability
Primary: Pharmacokinetics — 11.0 ng/dL
N/A N=70 A Pilot Study to Assess the DynaSense System
Pressure Ulcers
Primary: Safety Primary Endpoint — 2.86 percentage of subjects with ADEs
N/A N=70 ARemind: A Personalized System to Remind for Adherence
Medication Adherence
Primary: Adherence to Anti-retroviral Therapy — 0.69; 0.73; 0.62; .67 proportion adherence
N/A N=31 Investigation of Two Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy and Colostomy
Ileostomy - Stoma · Colostomy - Stoma
Primary: Degree of Leakage — 3.5; 3.1 units on a scale
Phase 3 N=234 A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Pulmonary Arterial Hypertension
Primary: Number of Participants Reporting at Least One Adverse Event — 41; 55; 73; 13 Participants
Phase 2 N=239 Study of Silodosin to Facilitate Passage of Urinary Stones
Ureteral Calculi · Kidney Stones · Urolithiasis
Primary: Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures…